A Phase 3 interventional study of OC-01 (varenicline) nasal spray and Placebo (vehicle) nasal spray in Dry Eye Disease (DED), sponsored by Oyster Point Pharma, Inc.. Completed at 22 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2021-11-22.
Sponsored by Oyster Point Pharma, Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing varenicline in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. Varenicline · Dry Eye Syndromes.
Among the 13 studies testing varenicline in Dry Eye Syndromes, this one has the largest enrollment, is one of 2 that started in 2019, is one of 4 in phase 3, and was the 4th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →2 of the 13 studies testing varenicline in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:
Ocular Aesthetics, LLC dba Ocular Clinical Trials · Sites in United States
Ages 18–99 · Healthy volunteers
University of California, Berkeley · Sites in United States
Ages 18+
By country, each count listing its studies:
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2019.
This study's enrollment of 758 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 13 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 9 most frequent:
This study is registered under Oyster Point Pharma, Inc., one of the names counted as Viatris Inc.. Under that name alone:
Oyster Point Pharma, Inc. is the lead sponsor of 11 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
Viatris Inc. has 9 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
2 of the studies testing varenicline in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07705893Ocular Aesthetics, LLC dba Ocular Clinical TrialsTreating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg | 2026-12 |
| NCT07606625University of California, BerkeleyOcular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing varenicline in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.
This was a Phase 3, multicenter, randomized, controlled, double-masked (including subjects, Investigators, study site personnel, and Sponsor personnel) study designed to evaluate the safety and efficacy of OC-01 (varenicline) nasal spray 0.6 mg/mL and 1.2 mg/mL in adult participants with DED. The study randomized 758 subjects at least 22 years of age with a physicians' diagnosis of DED and meeting all other study eligibility criteria to receive OC-01 (varenicline) nasal spray or placebo twice daily (BID) for 28 days with three additional long-term follow-up visits at 6 weeks, 6 months, and 12 months. Participants who terminated from the study during the treatment period were asked to complete safety assessments (if the participants agree) prior to study exit. Participants who were terminated early from the study were not replaced
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OC-01 (varenicline) nasal spray, 0.6 mg/ML
Drug: OC-01 (varenicline) nasal spray
OC-01 (varenicline) nasal spray, 1.2 mg/ML
Drug: OC-01 (varenicline) nasal spray
Placebo (vehicle) nasal spray
Drug: Placebo (vehicle) nasal spray
OC-01 (varenicline) nasal spray
Placebo (vehicle) nasal spray
Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28)
The primary endpoint was the percentage of subjects who achieve ≥10 mm improvement in Schirmer's Test Score from baseline to 28 days in the study eye following treatment with OC-01. Schirmer's test scores from 0-35 mm where a higher score is indicative of a better outcome.
Time frame: 28 Days [Visit 1 (baseline) and Visit 4b (28 days)]
Mean Change From Baseline in Eye Dryness Score in CAE at Week 4 at 5 Minutes
Change in Eye Dryness Score Eye from baseline in CAE at 4 Weeks at 5 minutes post treatment. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.
Time frame: 28 Days [Visit 1 (baseline) and Visit 4a (28 days)]
Mean Change From Baseline in Eye Dryness Score From Baseline to Day 28
Change in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.
Time frame: 28 Days [Visit 1 (baseline) and Visit 4b (28 days)]
Mean Change Form Baseline in Schirmer's Test Score From Baseline to Day 28
Change in Schirmer test score from baseline to Day 28. Schirmer's test scores from 0-35 mm where a higher score is indicative of a better outcome.
Time frame: 28 Days [Visit 1 (baseline) and Visit 4b (28 days)]
Mean Change From Baseline in Eye Dryness Score in the Study Eye at Week 2
Chang in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better otucome.
Time frame: 14 Days [Visit 1 (baseline) and Visit 3 (14 days)]
Mean Change From Baseline in Eye Dryness Score in the Study Eye at Week 1
Change in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.
Time frame: 7 Days [Visit 1 (baseline) and Visit 2 (7 days)]
| Milestone | OC-01 Low Dose 0.6 mg/mL BID for 28 Days | OC-01 High Dose 1.2 mg/mL BID for 28 Days | Placebo BID for 28 Days |
|---|---|---|---|
| Started | 260 | 246 | 252 |
| Completed | 239 | 212 | 228 |
| Not completed | 21 | 34 | 24 |
The primary endpoint was the percentage of subjects who achieve ≥10 mm improvement in Schirmer's Test Score from baseline to 28 days in the study eye following treatment with OC-01. Schirmer's test scores from 0-35 mm where a higher score is indicative of a better outcome.
| Participants | OC-01 Low Dose, 0.6 mg/mL | OC-01 High Dose, 1.2 mg/mL | Placebo (Vehicle) Nasal Spray |
|---|---|---|---|
| Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28) | 123 | 121 | 70 |
Change in Eye Dryness Score Eye from baseline in CAE at 4 Weeks at 5 minutes post treatment. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.
| mm | OC-01 Low Dose, 0.6 mg/mL | OC-01 High Dose, 1.2 mg/mL | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Eye Dryness Score in CAE at Week 4 at 5 Minutes | -10.3 ± 1.62 | -9.0 ± 1.75 | -7.4 ± 1.74 |
Change in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.
| mm | OC-01 Low Dose, 0.6 mg/mL | OC-01 High Dose, 1.2 mg/mL | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Eye Dryness Score From Baseline to Day 28 | -19.8 ± 1.54 | -22.2 ± 1.61 | -15.4 ± 1.57 |
Change in Schirmer test score from baseline to Day 28. Schirmer's test scores from 0-35 mm where a higher score is indicative of a better outcome.
| mm | OC-01 Low Dose, 0.6 mg/mL | OC-01 High Dose, 1.2 mg/mL | Placebo |
|---|---|---|---|
| Mean Change Form Baseline in Schirmer's Test Score From Baseline to Day 28 | 11.3 ± 0.61 | 11.5 ± 0.64 | 6.3 ± 0.61 |
Chang in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better otucome.
| mm | OC-01 Low Dose, 0.6 mg/mL | OC-01 High Dose, 1.2 mg/mL | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Eye Dryness Score in the Study Eye at Week 2 | -16.5 ± 1.38 | -17.9 ± 1.45 | -12.7 ± 1.41 |
Change in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.
| mm | OC-01 Low Dose, 0.6 mg/mL | OC-01 High Dose, 1.2 mg/mL | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Eye Dryness Score in the Study Eye at Week 1 | -15.7 ± 1.33 | -15.4 ± 1.40 | -13.3 ± 1.35 |
Collected over Adverse Events were collected from the first dose of study drug administration until the final study visit at Visit 7. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OC-01 Low Dose, 0.6 mg/mL | 0/260 (0%) | 5/260 (1.9%) | 253/260 (97.3%) |
| OC-01 High Dose, 1.2 mg/mL | 2/245 (0.8%) | 12/245 (4.9%) | 243/245 (99.2%) |
| Placebo | 1/251 (0.4%) | 9/251 (3.6%) | 158/251 (62.9%) |
| Event | OC-01 Low Dose, 0.6 mg/mL | OC-01 High Dose, 1.2 mg/mL | Placebo |
|---|---|---|---|
| Coronavirus infectionInfections and infestations | 0/260 | 1/245 | 1/251 |
| Diabetic gangreneInfections and infestations | 0/260 | 1/245 | 0/251 |
| GangreneInfections and infestations | 0/260 | 1/245 | 0/251 |
| BradycardiaCardiac disorders | 0/260 | 1/245 | 0/251 |
| Coronary artery diseaseCardiac disorders | 0/260 | 1/245 | 0/251 |
| Myocardial infarctionCardiac disorders | 0/260 | 1/245 | 0/251 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/260 | 1/245 | 0/251 |
| Cerebrovascular accidentNervous system disorders | 0/260 | 1/245 | 0/251 |
| Transient ischemic attackNervous system disorders | 0/260 | 1/245 | 0/251 |
| Deep vein thrombosisVascular disorders | 0/260 | 1/245 | 0/251 |
| Event | OC-01 Low Dose, 0.6 mg/mL | OC-01 High Dose, 1.2 mg/mL | Placebo |
|---|---|---|---|
| SneezingRespiratory, thoracic and mediastinal disorders | 247/260 | 237/245 | 73/251 |
| CoughRespiratory, thoracic and mediastinal disorders | 49/260 | 54/245 | 5/251 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 35/260 | 44/245 | 5/251 |
| Instillation site irritationGeneral disorders | 21/260 | 36/245 | 3/251 |
| NasopharyngitisInfections and infestations | 9/260 | 16/245 | 14/251 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 10/260 | 5/245 | 12/251 |
| conjunctival hyperaemiaEye disorders | 12/260 | 11/245 | 7/251 |
| Visual acuity reducedEye disorders | 9/260 | 9/245 | 11/251 |
| Nasal mucosal disorderRespiratory, thoracic and mediastinal disorders | 9/260 | 8/245 | 9/251 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 9/260 | 6/245 | 2/251 |
Subjects in the ITT population
| Age, Continuous(years) | OC-01 Low Dose 0.6 mg/mL BID for 28 Days | OC-01 High Dose 1.2 mg/mL BID for 28 Days | Placebo (Vehicle) Nasal Spray BID for 28 Days | Total |
|---|---|---|---|---|
| Mean | 59.6 ± 12.76 | 58.4 ± 13.03 | 58.4 ± 13.29 | 58.8 ± 13.02 |
| Sex: Female, Male(Participants) | OC-01 Low Dose 0.6 mg/mL BID for 28 Days | OC-01 High Dose 1.2 mg/mL BID for 28 Days | Placebo (Vehicle) Nasal Spray BID for 28 Days | Total |
|---|---|---|---|---|
| Female | 194 | 181 | 201 | 576 |
| Male | 66 | 65 | 51 | 182 |
| Ethnicity (NIH/OMB)(Participants) | OC-01 Low Dose 0.6 mg/mL BID for 28 Days | OC-01 High Dose 1.2 mg/mL BID for 28 Days | Placebo (Vehicle) Nasal Spray BID for 28 Days | Total |
|---|---|---|---|---|
| Hispanic or Latino | 27 | 37 | 36 | 100 |
| Not Hispanic or Latino | 233 | 209 | 216 | 658 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | OC-01 Low Dose 0.6 mg/mL BID for 28 Days | OC-01 High Dose 1.2 mg/mL BID for 28 Days | Placebo (Vehicle) Nasal Spray BID for 28 Days | Total |
|---|---|---|---|---|
| Race — American Indian or Alaska Native | 1 | 2 | 6 | 9 |
| Race — Asian | 11 | 7 | 5 | 23 |
| Race — Black or African American | 27 | 35 | 29 | 91 |
| Race — Native Hawaiian or other Pacific Islander | 2 | 0 | 1 | 3 |
| Race — White | 219 | 200 | 211 | 630 |
| Race — Other | 0 | 2 | 0 | 2 |
| Region of Enrollment(participants) | OC-01 Low Dose 0.6 mg/mL BID for 28 Days | OC-01 High Dose 1.2 mg/mL BID for 28 Days | Placebo (Vehicle) Nasal Spray BID for 28 Days | Total |
|---|---|---|---|---|
| United States | 260 | 246 | 252 | 758 |
| Baseline Schirmer's Test Score (mm)(mm) | OC-01 Low Dose 0.6 mg/mL BID for 28 Days | OC-01 High Dose 1.2 mg/mL BID for 28 Days | Placebo (Vehicle) Nasal Spray BID for 28 Days | Total |
|---|---|---|---|---|
| Mean | 5.1 ± 2.95 | 5.4 ± 2.93 | 4.9 ± 2.89 | 5.1 ± 2.93 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2019 to primary completion in Apr 2020, 8 months.
Results were first posted in Nov 2021, 1 year 7 months after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 8 months is below that.
Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline